Avelardo Valdez1, Alan Neaigus, Charles Kaplan, Alice Cepeda. 1. Graduate College of Social Work, Center for Drug & Social Policy Research, University of Houston, 110HA Social Work, Houston, TX 77204-4013, USA. avaldez2@uh.edu
Abstract
OBJECTIVE: To assess the incidence and rate of transition to injecting among Mexican American noninjecting heroin users. METHODS: In a prospective cohort study of street-recruited MA-NIU in San Antonio, Texas, 2002-2005, participants were administered structured interviews and tested for Human immunodeficiency virus (HIV), hepatitis B virus (HBV) and hepatitis C virus (HCV). The analysis sample comprised former injection drug users (last injected >6 months ago, n=47) and those who had never injected drugs and tested HCV negative (n=219). A transition to injecting was defined as the first injection of illicit drugs since baseline interview. Transition rates were based on person-years at-risk (PYAR). Proportional hazards regression was used to estimate crude and adjusted (for significant differences between former and never injectors) hazard ratios and 95% confidence intervals of injecting history on transitioning to injecting. RESULTS: Sixty-three (24%) participants transitioned to injecting at a rate of 22.3/100 PYAR (95% CI: 17.2-28.2). Former-injectors were significantly more likely to transition than never injectors (43% or 20/47 vs. 20% or 43/219; p<0.001), and did so at a faster rate (40.4/100 PYAR, 95% CI: 24.6-60.0 vs. 18.5/100 PYAR, 95% CI: 13.4-24.4), with the crude HR=1.931 (95% CI: 1.116, 3.341) and adjusted HR=2.263 (95% CI: 1.192-4.294). CONCLUSIONS: The rate of transitioning to injecting was high and greater among former injectors. Of particular concern is the high rate of injecting initiation among never injectors. Future analyses will examine factors associated with injecting initiation, including individual susceptibility and behaviors, social networks, and the cultural and drug market context.
OBJECTIVE: To assess the incidence and rate of transition to injecting among Mexican American noninjecting heroin users. METHODS: In a prospective cohort study of street-recruited MA-NIU in San Antonio, Texas, 2002-2005, participants were administered structured interviews and tested for Human immunodeficiency virus (HIV), hepatitis B virus (HBV) and hepatitis C virus (HCV). The analysis sample comprised former injection drug users (last injected >6 months ago, n=47) and those who had never injected drugs and tested HCV negative (n=219). A transition to injecting was defined as the first injection of illicit drugs since baseline interview. Transition rates were based on person-years at-risk (PYAR). Proportional hazards regression was used to estimate crude and adjusted (for significant differences between former and never injectors) hazard ratios and 95% confidence intervals of injecting history on transitioning to injecting. RESULTS: Sixty-three (24%) participants transitioned to injecting at a rate of 22.3/100 PYAR (95% CI: 17.2-28.2). Former-injectors were significantly more likely to transition than never injectors (43% or 20/47 vs. 20% or 43/219; p<0.001), and did so at a faster rate (40.4/100 PYAR, 95% CI: 24.6-60.0 vs. 18.5/100 PYAR, 95% CI: 13.4-24.4), with the crude HR=1.931 (95% CI: 1.116, 3.341) and adjusted HR=2.263 (95% CI: 1.192-4.294). CONCLUSIONS: The rate of transitioning to injecting was high and greater among former injectors. Of particular concern is the high rate of injecting initiation among never injectors. Future analyses will examine factors associated with injecting initiation, including individual susceptibility and behaviors, social networks, and the cultural and drug market context.
Authors: Tim Rhodes; Catherine Lowndes; Ali Judd; Larissa A Mikhailova; Anya Sarang; Andrey Rylkov; Mikhail Tichonov; Kim Lewis; Nina Ulyanova; Tatiana Alpatova; Victor Karavashkin; Mikhail Khutorskoy; Matthew Hickman; John V Parry; Adrian Renton Journal: AIDS Date: 2002-09-06 Impact factor: 4.177
Authors: Alan Neaigus; V Anna Gyarmathy; Maureen Miller; Veronica M Frajzyngier; Samuel R Friedman; Don C Des Jarlais Journal: J Acquir Immune Defic Syndr Date: 2006-04-01 Impact factor: 3.731
Authors: Ricky N Bluthenthal; Lynn Wenger; Daniel Chu; Jennifer Lorvick; Brendan Quinn; James P Thing; Alex H Kral Journal: Drug Alcohol Depend Date: 2015-02-19 Impact factor: 4.492
Authors: Alice Cepeda; Charles Kaplan; Alan Neaigus; Miguel Ángel Cano; Yolanda Villarreal; Avelardo Valdez Journal: Drug Alcohol Depend Date: 2012-06-30 Impact factor: 4.492
Authors: Ricky N Bluthenthal; Lynn Wenger; Daniel Chu; Brendan Quinn; James Thing; Alex H Kral Journal: Drug Alcohol Depend Date: 2014-09-18 Impact factor: 4.492